Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,646
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience

Luigi Gargiuloa Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Luciano Ibbaa Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence[email protected]
View further author information
,
Carlo Alberto Vignolia Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Paola Facherisa Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyView further author information
,
Mario Valentia Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Antonio Costanzoa Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
&
Alessandra Narcisia Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, ItalyView further author information
 show all
Article: 2216815 | Received 09 May 2023, Accepted 11 May 2023, Published online: 29 May 2023

References

  • Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 Suppl 1:1–3.
  • Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431.
  • Gargiulo L, Vignoli CA, Ibba L, et al. Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study. J Dermatolog Treat. 2023;34(1):2200867.
  • Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449.
  • Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–463.
  • European Medicines Agency. Adtralza (tralokinumab): summary of product characteristics. 2021 [cited 2023 May 02]. Available from: https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf
  • Pereyra-Rodriguez JJ, Herranz P, Ruiz-Villaverde R, et al. Treatment of severe atopic dermatitis with tralokinumab in real clinical practice. Short-term effectiveness and safety results. Clin Exp Dermatol. 2023 [cited 2023 Apr 25]; llad153.
  • Gargiulo L, Ibba L, Cortese A, et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther. 2023;13(2):651–660.
  • Touhouche AT, Cassagne M, Bérard E, et al. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol. 2021;35(1):172–179.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.